Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Tier-Classified Guidelines Database


Genomics & Health Impact Scan Database|Search|PHGKB

Last data update: Oct 04, 2023. (Total: 530 Documents since 2012)
   dataset
Filtered By:
Records 1-30 (of 347 Record(s))
Reminder!

The tier level is assigned to the guideline, NOT to the specific search terms. For example, a Tier 1 guideline has at least one recommendation that meets criteria for Tier 1, but also could include tier 2 or 3 recommendations.
DO read the guidelines to find out about specific search terms.
DON’T rely on the overall tier classification of the guideline for the specified search terms.
See More FAQ

Next
Query Trace: All[original query]>>2[Tier]
Publication Tier
AGA Clinical Practice Update on Risk Stratification for Colorectal Cancer Screening and Post-Polypectomy Surveillance: Expert Review.
Rachel B Issaka et al. Gastroenterology 2023
Tier 2
Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals.
Laura Obici et al. BMJ Open 2023 13(9) e073130
 Tier 2
Indications and management of preimplantation genetic testing for monogenic conditions: a committee opinion.
et al. Fertil Steril 2023
Tier 2
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance.
Marina Cuchel et al. Eur Heart J 2023
Tier 2
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.
Chad A Bousman et al. Clinical pharmacology and therapeutics 2023
Tier 2
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.
Lianne Beunk et al. European journal of human genetics : EJHG 2023
Tier 2
Genetic evaluation of living kidney donor candidates: A review and recommendations for best practices.
Christie P Thomas et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2023
Tier 2
Genetic and metabolic investigations for neurodevelopmental disorders: position statement of the Canadian College of Medical Geneticists (CCMG).
Melissa T Carter et al. Journal of medical genetics 2023
Tier 2
Updated clinical practice recommendations for managing adults with 22q11.2 deletion syndrome.
Erik Boot et al. Genetics in medicine : official journal of the American College of Medical Genetics 2023 100344
 Tier 2
Updated clinical practice recommendations for managing children with 22q11.2 deletion syndrome.
Sólveig Óskarsdóttir et al. Genetics in medicine : official journal of the American College of Medical Genetics 2023 100338
 Tier 2
Guidelines for the Diagnosis and Treatment of Adult Familial Hypercholesterolemia 2022.
Mariko Harada-Shiba et al. Journal of atherosclerosis and thrombosis 2023
Tier 2
International Consensus Guideline on Small for Gestational Age (SGA): Etiology and Management from Infancy to Early Adulthood.
Hokken-Koelega Anita C S et al. Endocrine reviews 2023
Tier 2
Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate.
Nijenhuis Marga et al. European journal of human genetics : EJHG 2022
Tier 2
Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.
Hulshof Emma C et al. European journal of human genetics : EJHG 2022
Tier 2
Dutch pharmacogenetics working group guideline for the gene-drug interaction of ABCG2, HLA-B and Allopurinol, and MTHFR, folic acid and methotrexate.
van der Pol Karel H et al. European journal of human genetics : EJHG 2022
Tier 2
cancer predisposition risk assessment system
The U.S. Food and Drug Administration (FDA)
 Tier 2
ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
Miller David T et al. Genetics in medicine : official journal of the American College of Medical Genetics 2022 24(7) 1407-1414
 Tier 2
Clinical evaluation and etiologic diagnosis of hearing loss: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).
Li Marilyn M et al. Genetics in medicine : official journal of the American College of Medical Genetics 2022 24(7) 1392-1406
 Tier 2
Consensus Recommendations of the German Consortium for Hereditary Breast and Ovarian Cancer.
Rhiem Kerstin et al. Breast care (Basel, Switzerland) 2022 17(2) 199-207
 Tier 2
Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK.
Gillmore Julian D et al. Advances in therapy 2022
Tier 2
European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases.
Wilde Arthur A M et al. Heart rhythm 2022
Tier 2
Expert Consensus on the Use of Prognostic Gene Expression Profiling Tests for the Management of Cutaneous Melanoma: Consensus from the Skin Cancer Prevention Working Group.
Farberg Aaron S et al. Dermatology and therapy 2022
Tier 2
The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms.
Cooper-DeHoff Rhonda M et al. Clinical pharmacology and therapeutics 2022
Tier 2
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.
Lee Craig R et al. Clinical pharmacology and therapeutics 2022
Tier 2
next generation sequencing based tumor profiling test
The U.S. Food and Drug Administration (FDA)
 Tier 2
rt-qpcr assay for mrna transcript immune biomarkers
The U.S. Food and Drug Administration (FDA)
 Tier 2
lynch syndrome test system
The U.S. Food and Drug Administration (FDA)
 Tier 2
International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia.
Savarirayan Ravi et al. Nature reviews. Endocrinology 2021
Tier 2
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer Jurriaan M J L et al. European journal of human genetics : EJHG 2021
Tier 2
Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021.
Izar Maria Cristina de Oliveira et al. Arquivos brasileiros de cardiologia 2021 117(4) 782-844
 Tier 2
TOP